Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

y authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267 or that TorreyPines will be able to reach agreement with a partner for any of the product candidates or programs on terms that are acceptable to TorreyPines. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Craig Johnson

TorreyPines Therapeutics, Inc.

858-623-5665, x158

cjohnson@torreypinestherapeutics.com

Media Contact:

David Schull

Russo Partners, LLC

212-845-4271

david.schull@russopartners.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@RxIR.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... LMNX ) announced today that it has joined ... Match to raise awareness of the need for additional donors ... growing number of patients awaiting life-saving bone marrow transplants.  Recently, ... Registry in an effort to assist patients nationwide. Luminex will ...
... Oct. 5, 2011 SRI International has been awarded ... $14.3 million. The contracts provide SRI up to $11.7 ... for pharmacology and pharmacokinetics studies that will be carried ... These five-year contracts extend SRI,s preclinical studies for the ...
... Oct. 5, 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: ... central nervous system diseases, announced today that James S. Kuo, ... provide a brief update on its Alzheimer,s program at the ... companies at the invitation-only event on Tuesday evening, October 11, ...
Cached Biology Technology:Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 2Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 3Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 4SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 2SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts 3Adeona CEO to Present at the NYC Medtech Forum 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... treatment, but it,s not always effective. Successful chemotherapy depends ... the bloodstream through the leaky blood vessels that often ... of individuals from unnecessary toxicity and the often difficult ... published in the February issue of the journal ...
... USA, February 1, 2009 A special Supplement to ... the American Dietetic Association presents findings from the ... conducted by Mathematica Policy Research, Inc., as well as ... the Food and Nutrition Service of the US Department ...
... Screening a chemical library of 200,000 compounds, researchers at ... that can be used to study and possibly manipulate ... and degenerative diseases. "The identification of these chemicals ... important step in developing therapeutic agents," said Dr. Lawrence ...
Cached Biology News:New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome 2New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome 3Results of the third school nutrition dietary assessment study published 2Results of the third school nutrition dietary assessment study published 3Results of the third school nutrition dietary assessment study published 4UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease 2
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Open-slot design for easy ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Mammals microRNA Microarray ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: